Regulation of the interaction between the neuronal BIN1 isoform 1 and Tau proteins – role of the SH3 domain

Bridging integrator 1 (bin1) gene is a genetic determinant of Alzheimer's disease (AD) and has been reported to modulate Alzheimer's pathogenesis through pathway(s) involving Tau. The functional impact of Tau/BIN1 interaction as well as the molecular details of this interaction are still not fully resolved. As a consequence, how BIN1 through its interaction with Tau affects AD risk is also still not determined. To progress in this understanding, interaction of Tau with two BIN1 isoforms was investigated using Nuclear Magnetic Resonance spectroscopy. 1H, 15N spectra showed that the C‐terminal SH3 domain of BIN1 isoform 1 (BIN1Iso1) is not mobile in solution but locked with the core of the protein. In contrast, the SH3 domain of BIN1 isoform 9 (BIN1Iso9) behaves as an independent mobile domain. This reveals an equilibrium between close and open conformations for the SH3 domain. Interestingly, a 334–376 peptide from the clathrin and AP‐2‐binding domain (CLAP) domain of BIN1Iso1, which contains a SH3‐binding site, is able to compete with BIN1‐SH3 intramolecular interaction. For both BIN1 isoforms, the SH3 domain can interact with Tau(210–240) sequence. Tau(210–240) peptide can indeed displace the intramolecular interaction of the BIN1‐SH3 of BIN1Iso1 and form a complex with the released domain. The measured Kd were in agreement with a stronger affinity of Tau peptide. Both CLAP and Tau peptides occupied the same surface on the BIN1‐SH3 domain, showing that their interaction is mutually exclusive. These results emphasize an additional level of complexity in the regulation of the interaction between BIN1 and Tau dependent of the BIN1 isoforms.

[1]  P. Verstreken,et al.  Loss of Bin1 Promotes the Propagation of Tau Pathology. , 2016, Cell reports.

[2]  A. Rodal,et al.  Coordinated autoinhibition of F-BAR domain membrane binding and WASp activation by Nervous Wreck , 2016, Proceedings of the National Academy of Sciences.

[3]  Richard C. Rice,et al.  Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts , 2016, Molecular Neurodegeneration.

[4]  S. Seshadri,et al.  Subcellular Changes in Bridging Integrator 1 Protein Expression in the Cerebral Cortex During the Progression of Alzheimer Disease Pathology , 2016, Journal of neuropathology and experimental neurology.

[5]  S. Tsuji,et al.  BIN1 regulates BACE1 intracellular trafficking and amyloid-β production. , 2016, Human molecular genetics.

[6]  H. Soininen,et al.  Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology , 2016, Molecular Psychiatry.

[7]  A. Rodal,et al.  Membrane Charge Directs the Outcome of F-BAR Domain Lipid Binding and Autoregulation. , 2015, Cell reports.

[8]  J. Lambert,et al.  Tau phosphorylation regulates the interaction between BIN1’s SH3 domain and Tau’s proline-rich domain , 2015, Acta neuropathologica communications.

[9]  T. Baumgart,et al.  BIN1 Membrane Curvature Sensing and Generation Show Autoinhibition Regulated by Downstream Ligands and PI(4,5)P2 , 2014, Biochemistry.

[10]  J. Laporte,et al.  Amphiphysin 2 (BIN1) in physiology and diseases , 2014, Journal of Molecular Medicine.

[11]  T. Baumgart,et al.  Intradimer/Intermolecular Interactions Suggest Autoinhibition Mechanism in Endophilin A1 , 2014, Journal of the American Chemical Society.

[12]  Christopher A. Waudby,et al.  Protein folding on the ribosome studied using NMR spectroscopy , 2013, Progress in nuclear magnetic resonance spectroscopy.

[13]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[14]  M. Owen,et al.  Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology , 2013, Molecular Psychiatry.

[15]  P. Permi,et al.  SH3 domain ligand binding: What's the consensus and where's the specificity? , 2012, FEBS letters.

[16]  Xinchen Wang,et al.  Tissue-specific alternative splicing remodels protein-protein interaction networks. , 2012, Molecular cell.

[17]  T. Sixma,et al.  Enabling high-throughput ligation-independent cloning and protein expression for the family of ubiquitin specific proteases. , 2011, Journal of structural biology.

[18]  A. Ittner,et al.  Brief update on different roles of tau in neurodegeneration , 2011, IUBMB life.

[19]  P. Bosco,et al.  APOE and Alzheimer disease: a major gene with semi-dominant inheritance , 2011, Molecular Psychiatry.

[20]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[21]  Ezzie Hutchinson,et al.  Systems neuroscience: The stress of dieting , 2011, Nature Reviews Neuroscience.

[22]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[23]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[24]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[25]  Thomas Szyperski,et al.  A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. , 2005, Journal of molecular biology.

[26]  Wayne Boucher,et al.  The CCPN data model for NMR spectroscopy: Development of a software pipeline , 2005, Proteins.

[27]  C. Dobson,et al.  Heteronuclear NMR investigations of dynamic regions of intact Escherichia coli ribosomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Akke,et al.  Conformation and dynamics of ribosomal stalk protein L12 in solution and on the ribosome. , 2004, Biochemistry.

[29]  B. Peter,et al.  BAR Domains as Sensors of Membrane Curvature: The Amphiphysin BAR Structure , 2004, Science.

[30]  Markus R Wenk,et al.  Amphiphysin 2 (Bin1) and T-Tubule Biogenesis in Muscle , 2002, Science.

[31]  A. Delacourte,et al.  Tau pathology: a marker of neurodegenerative disorders , 2000, Current opinion in neurology.

[32]  Pietro De Camilli,et al.  Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis , 1999, Nature Cell Biology.

[33]  Robert Wechsler-Reya,et al.  BIN1 is a novel MYC–interacting protein with features of a tumour suppressor , 1996, Nature Genetics.

[34]  P. De Camilli,et al.  A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Schreiber,et al.  Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. , 1995, Science.

[36]  Hongtao Yu,et al.  Structural basis for the binding of proline-rich peptides to SH3 domains , 1994, Cell.

[37]  P Cicchetti,et al.  Identification of a ten-amino acid proline-rich SH3 binding site. , 1993, Science.

[38]  M. Murphy,et al.  Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. , 2014, Journal of Alzheimer's disease : JAD.

[39]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[40]  Wendell A. Lim,et al.  Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains , 1995, Nature.